Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead (GILD) delivered earnings and revenue surprises of -54.90% and 9.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q4 Earnings Miss Estimates

GlaxoSmithKline

GlaxoSmithKline PLC announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc on Tuesday in relation to patent violations by Gilead's Biktarvy, a medicine to treat human immunodeficiency virus.

GSK announces $1.25 billion settlement between ViiV Healthcare, Gilead

Gilead Sciences Inc. beat Wall Street's expectations for revenue in the fourth quarter, but the drug maker's earnings were hit by $2 billion in unexpected costs, most of it due to a legal settlement

Gilead earnings slammed by legal settlement, stock falls

Gilead Sciences Inc on Tuesday posted lower-than-expected fourth-quarter earnings, citing a $1.25 billion legal settlement involving HIV drug patents and a charge related to its collaboration with Arcus Biosciences Inc.

Gilead earnings dip due to legal settlement, other charges

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 2.8% in the company's quarterly cash dividend, beginning in the first quarter of 2022. The increase will result in a quarterly dividend of $0.73 per share of common stock. The dividend is payable on March 30, 2022, to stockholders of record at the close of business on March 15, 2022. Future dividends will be subject to Board approval. About

Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021. “Gilead is at an important point in its transformation journey, having built considerable momentum in the expansion of our commercial and clinical portfolios in both virology and oncology in 2021,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “We are planning to further increase the number of clinical development stu

Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick Gilead Sciences (GILD) Stock?

Amgen

Bristol-Myers

Biotech's blue bloods are the best bets in the space right now.

How to Invest in Biotech When Deep Value Has no Discernible Meaning

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta® (axicabtagene ciloleucel) to include use of prophylactic corticosteroids across all approved indications. Yescarta is now the first and only chimeric antigen receptor (CAR) T-cell therapy with information in the label to help physicians manage, and potentially prevent, treatment side effects.

U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome

It is currently benefiting from a pandemic tailwind, but for how much longer?

Is Gilead Sciences Stock a Buy Now?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

Alphabet

Thermo Fisher Scientific

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

5 Corporate Giants Likely to Gain From Q4 Earnings Next Week

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

Due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between study arms, the agency has taken action.

FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings

IRVING, Texas--(BUSINESS WIRE)--Vizient announced that remdesivir, used to treat COVID, now tops its list of drugs by total member spend, replacing the anti-inflammatory adalimumab.

Vizient Pharmacy Market Outlook: Increased Use of Remdesivir for COVID Pushes it to Top Spot in Total Vizient Member Spend

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial cli

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

Eli Lilly

Merck

Pfizer

Regeneron Pharmaceuticals

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates

Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

Gilead (GILD) Drug Gets FDA Nod for Non-Hospitalized COVID Patients

The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) for non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19.  This approval expands the role of Veklury, which is the antiviral standard of care for treating patients hospitalized with COVID-19.

FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treat

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

The biopharmaceutical company Gilead Sciences announced Wednesday a massive web of seizures across several states of "counterfeit and tampered Gilead HIV medication within the U.S. supply chain."

Gilead announces massive seizure of counterfeit HIV-1 drugs

Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years. The alleged scheme was reported earlier by The Wall Street Journal.

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Johnson & Johnson

GlaxoSmithKline PLC ( GSK , Financial), Pfizer Inc. ( PFE , Financial) and Johnson & Johnson ( JNJ , Financial) should all know about mid-year if the shots they're developing for a common and potentially fatal virus is effective. No, the it isn't for Covid-19, but for respiratory syncytial virus, which causes an estimated 177,000 hospitalizations among older adults each year and 58,000 in children under five.

News for Gilead Sciences Stock (GILD)